Synergy Biomedical, a novel biomaterial products development company, has received FDA 510(k) clearance for its BIOSPHERE PUTTY as a bone graft extender used in the posterolateral spine.
"The expanded clearance will give spine surgeons access to a next generation bioactive bone graft product that can be used in challenging spine fusion surgery. The clearance will also allow us to greatly expand our growing distribution network and get the product into more surgeons' hands," said Synergy president and CEO Mark Borden, PhD.
BIOSPHERE PUTTY is the company's that uses patented bioactive glass spheres. The product has the highest bioactive glass content on the market.
More Articles on Devices:
Biomet, Medtronic, Misonix & more – 7 Key Notes
RTI Surgical Unveils Precision Allograft Cartilage Kit
St. Jude Medical Pays $200M for NeuroTherm: 5 Facts on the Transaction